Weekly founder insights · Japan → U.S.

Strategy

Regulatory, quality and market-entry decisions for your next U.S. milestone.

For Japanese medical-device, diagnostics and regulated medical-AI founders entering the United States.

Showing the dated edition below. Weekly updates are being connected.

1. Proposed FDA guidance agenda · Recent · 2026-10-01

   FDA prioritizes medical AI lifecycle and change-control guidance

   What changed: FDA’s FY2027 agenda prioritizes final guidance on AI device software lifecycle management, predetermined change control plans and quality-system information for certain submissions.

   Founder implication · interpretation: Japanese medical-AI teams should anticipate evolving documentation and update-management expectations when planning U.S. development milestones.

   Next action: Compare the agenda with your submission calendar, monitor publication and consider comments by November 30.

   What to confirm: An agenda to finalize guidance is not issued final guidance. Priorities and publication timing may change.

   Primary sources:FDA · FY2027 proposed guidance agendaFDA · FY2027 guidance agenda documentFDA · CDRH news and updates
2. Final order: requested partial exemption denied · Recent · 2026-09-17

   Radiology AI: the requested broad 510(k) exemption was denied

   What changed: A September final order confirmed FDA’s denial of a proposed partial 510(k) exemption for specified radiology detection, diagnosis, triage and notification software. The denial was issued April 1.

   Founder implication · interpretation: An earlier clearance does not create the broad exemption sought for subsequent products.

   Next action: Retain the applicable regulatory pathway and submission budget; assess each intended use and modification before U.S. commercialization.

   What to confirm: The order did not grant an exemption. Requirements remain product- and modification-specific; the September order became effective September 17, 2026.

   Primary sources:FDA / Federal Register · Radiology software exemption final order
3. Recurring annual registration window is open · Ongoing · 2026-02-02

   Foreign manufacturers: verify FDA registration by December 31

   What changed: The annual October 1–December 31 establishment-registration verification window is open. Foreign manufacturers subject to registration must designate a U.S. Agent.

   Founder implication · interpretation: Japanese manufacturers need an accountable owner coordinating the Japanese entity, U.S. Agent, device listings and required fee payment.

   Next action: Confirm your establishment’s obligations, reconcile device and contact information, and complete verification before December 31.

   What to confirm: This is an existing annual obligation, not a new 2026 policy. Registration does not confer marketing authorization; assess exemptions and establishment roles individually.

   Primary sources:FDA · Overview of device regulation